ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Diosgenin inhibits prostate cancer progression by inducing UHRF1 protein degradation

Peng, Yuchong; Tang, Rong; Ding, Liuyang; Zheng, Rirong; Liu, Youhong; Yin, Linglong; Fu, Yongming; Deng, Tanggang; Li, Xiong*广东药学院; 1
European Journal of Pharmacology2023-3-5DOI: 10.1016/j.ejphar.2023.175522
4被引12阅读
引用收藏
分享

摘要

Prostate cancer (PCa) represents the second cause of cancer death in adult men. Aberrant overexpression of UHRF1 has been reported in several cancer types, and is regarded as a novel drug target for cancer therapy. Nevertheless, no UHRF1-targeted small molecule inhibitor has been testing in clinical trials. Traditional Chinese medicine (TCM) prescriptions have a long history for the treatment of PCa in China, and Chinese herbal extracts are important resources for new drug discovery. In the present study, we first screened the potentially effective components from the commonly used TCMs for PCa treatment in clinic by using network pharmacology together with molecular docking. We identified diosgenin (DSG) as a small molecule natural compound specifically targeting UHRF1 protein. Furthermore, we validated the results by using the wet lab experiments. DSG, by directly binding UHRF1 protein, induced UHRF1 protein degradation through the ubiquitin-proteasome pathway. Importantly, DSG induced UHRF1 protein degradation by reducing the protein interaction with a deubiquitinase USP7. DSG reduced the level of genomic DNA methylation, and elevated the expression of such tumor suppressor genes as p21, p16 and LXN, thereby resulting in cell cycle arrest, cellular senescence and the inhibition of xenograft tumor growth. We here presented the first report that DSG specifically induced UHRF1 protein degradation, thereby revealing a novel anticancer mechanism of DSG. Altogether, this present study provided a promising strategy to discover new molecule-targeted drugs from small-molecule natural products.

学科与关键词

关键词
Traditional Chinese MedicineProstate cancerDiosgeninDNA methylationTumor suppressor genes
相关
加载中…

文献加载失败,请重试

重试

发表信息

论文状态
公开发表
期刊
European Journal of Pharmacology
发表日期
2023-03-05
卷期
第 942 卷
页码
175522
DOI
10.1016/j.ejphar.2023.175522
语言
ENGLISH
成果收录
SCIE
资助标注
National Natural Science Foundation of China [NSFC 81572542, 81874096]; Research Project of Key Discipline of Guangdong Province [2019GDXK0010]; Science and Technology Program of Guangzhou City (The roles of AR mitochondrial translocation in the development of anti -androgen drug resistance in prostate cancer); National Key Clinical Specialty Construction Project (Clinical Pharmacy); High Level Clinical Key Specialty (Clinical Pharmacy) in Guangdong Province

作者

  • P

    Peng, Yuchong (第一作者)

    1 · guangdong pharmaceut univ

  • T

    Tang, Rong

    1 · guangdong pharmaceut univ

查看全部 9 位作者收起作者
  • D

    Ding, Liuyang

    1 · guangdong pharmaceut univ

  • Z

    Zheng, Rirong

    1 · guangdong pharmaceut univ

  • L

    Liu, Youhong

  • Y

    Yin, Linglong

    1 · guangdong pharmaceut univ

  • F

    Fu, Yongming

    1 · guangdong pharmaceut univ

  • D

    Deng, Tanggang

    1 · guangdong pharmaceut univ

  • L

    Li, Xiong (通讯)

    1 · guangdong pharmaceut univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417